Trillium Therapeutics Inc.
CD47 BLOCKADE THERAPY

Abstract:

CD47+ disease cells, such as various cancers, are treated using a combination of CD47 blockade with T cell checkpoint inhibition. Preferred embodiments use SIRP.alpha.Fc in combination with a PD-1 pathway inhibitor such as nivolumab and/or a CTLA-4 inhibitor such as ipilimumab.